The practice of precision medicine utilizes advanced diagnostic tools to identify specific groups of patients on the basis of particular molecular characteristics, and guide their treatment with therapeutics that are selectively active against disease cases which harbor these characteristics. This approach is transforming the care that patients receive, particularly in oncology. In this presentation, Dr. Benjamin Chaffey and Dr. David Hout will firstly introduce the QIAGEN therascreen® FGFR RGQ RT-PCR Kit, which was recently co-approved by the FDA as the companion diagnostic test to guide prescription of BALVERSA™, a novel FGFR inhibitor, in cases of urothelial cancer. They will then describe how patient access to testing has been made available as rapidly as possible through Insight Genetics’ participation in the QIAGEN Day-One Readiness program for this test.
1. To gain a more complete understanding of the importance of FGFR testing when identifying treatment options for patients suffering with advanced urothelial cancer
2. To learn how the Day-One Readiness program enables QIAGEN and partner labs such as Insight to accelerate the availability of innovative new tests to health care providers and thereby improve the quality of care which can be delivered to patients.